Exportación Completada — 

Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma

PURPOSE: BRAF inhibitors are clinically active in patients with advanced BRAF(V600)-mutant melanoma, although acquired resistance remains common. Preclinical studies demonstrated that resistance could be overcome using concurrent treatment with the HSP90 inhibitor XL888. METHODS: Vemurafenib (960 mg...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Eroglu, Zeynep, Chen, Y. Ann, Gibney, Geoffrey T., Weber, Jeffrey S., Kudchadkar, Ragini R., Khushalani, Nikhil I., Markowitz, Joseph, Brohl, Andrew S., Tetteh, Leticia F., Ramadan, Howida, Arnone, Gina, Li, Jiannong, Zhao, Xiuhua, Sharma, Ritin, Darville, Lancia N.F., Fang, Bin, Smalley, Inna, Messina, Jane L., Koomen, John M., Sondak, Vernon K., Smalley, Keiran S.M.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6195480/
https://ncbi.nlm.nih.gov/pubmed/29674508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0565
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares